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Summary Efficacy and tolerability of tiagabine was evaluated in patients with non-
controlled partial seizures in a multicentre, open-label, parallel group study. Tiaga-
bine was administered either two (b.i.d.) or three times daily (t.i.d.) as adjunctive
therapy and titrated stepwise to a target of 40 mg/day during a 12-week, fixed-
schedule titration period; this was followed by a 12-week flexible continuation
period. The primary efficacy endpoint was the proportion of patients completing
the fixed-schedule titration period. A total of 243 patients were randomised and
received treatment, 123 to b.i.d. and 120 to t.i.d. dosing. Fewer patients in the b.i.d.
(76 and 62%) than in the t.i.d. (87 and 72%) group completed the fixed-schedule
titration period (OR: 0.562; 95% CI: 0.309—1.008; P = 0.0532). Themedian percentage
decrease in all types of seizure (excluding status epilepticus) during the fixed
schedule titration period was 33.4% for the b.i.d. and 23.8% for the t.i.d. groups
(P = 0.9634; Van Elteren’s test). The proportion of responders was similar for the
b.i.d. and t.i.d. groups. There were no significant differences between dosage
regimens in the change in median seizure rates from baseline. Adverse events were
more frequent during the titration than the continuation period. Most events were
mild and related to the central nervous system. Although their incidence was similar
between treatment groups, severity was more frequent in the b.i.d. group. Our
results suggest that during titration tiagabine is better tolerated with t.i.d. dosing,
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but during long-term maintenance, a t.i.d. schedule is as effective and well tolerated
as b.i.d.
# 2004 Published by Elsevier Ltd on behalf of BEA Trading Ltd.Introduction
Tiagabine inhibits seizures by increasing the synap-
tosomal concentrations of the inhibitory neuro-
transmitter g-aminobutyric acid (GABA). After
rapid absorption following oral administration, the
drug undergoes extensive metabolism in the liver.1
Its half-life is 7—9 h in non-enzyme induced patients
and about 3 h in induced patients. Thus, frequent
daily dosing has been advocated. Several rando-
mised, double-blind trials have shown that three
times daily (t.i.d.) dosing is adequate for use and
this dosing has been recommended in the tiagabine
label.2 However, broad clinical experience has sug-
gested that a two times daily (b.i.d.) tiagabine
regimen may also be effective and well tolerated.
This study represents a prospective assessment of
the efficacy and tolerability of two tiagabine dosing
regimens (b.i.d. and t.i.d.) in patients with epilepsy
from 31 centres in the UK and Spain.Methods
Patients
Male and female patients aged 12 years who were
diagnosed with partial seizures, with or without
secondary generalisation, at least 6 months prior
to study entry were enrolled. Additional criteria
included at least four partial seizures during an 8-
week period before study start. Patients gave writ-
ten informed consent to participate and the study
was approved under local ethics legislation and
in accordance with GCP and the Declaration of
Helsinki.
Design
This open-label, randomised, parallel-group study
involved 31 centres in the UK and Spain and com-
prised an initial 12-week fixed schedule titration
period of add-on tiagabine, followed by a 12-week,
open-continuation period.
Eligible patients were randomised to receive tia-
gabine either b.i.d. or t.i.d., titrated after the first
dose of 10 mg/day, in increments, to a target daily
dose of 40 mg/day within 6 weeks (Fig. 1). If a dose
increase step was not tolerated, patients were
maintained on the highest tolerated dose level at
that dosing frequency. The dose could be altered bythe investigator within the range 30—70 mg/day
during the flexible continuation phase.
Statistical analysis
The primary endpoint was the proportion of patients
completing the fixed-schedule titration period
(intent-to-treat (ITT) population) and results are
presented as odds ratios (OR) with associated con-
fidence intervals (CI) [an OR > 1 means more
patients completing in the BID group]. A secondary
variable, the median percentage change in seizure
rate (per 28 days) from baseline to 12 weeks in the
‘patients with seizure data’ population (an ITT sub-
set that provided seizure data for the fixed-schedule
titration period), was assessed using Van Elteren’s
method.3 The number of responders with 50%
reduction in seizures was analysed by Fisher’s Exact
Test. All statistical tests were two-sided with a
significance level of 0.05.Results
Patient disposition
The ITT population comprised 243 patients receiving
tiagabine (123 b.i.d., 120 t.i.d.). Of these, 80 had
incomplete seizure data for the duration of the
fixed-schedule titration period. Thus, 163 patients
comprised the ‘patients with seizure data’ subset
(76 b.i.d., 87 t.i.d.). The treatment groups were
well matched for baseline characteristics. The most
frequent type of seizure was complex partial (102/
123 b.i.d., 101/120 t.i.d.).
Efficacy
Fewer patients in the b.i.d. group than in the t.i.d.
group completed the fixed-schedule titration per-
iod, 76 (61.8%) and 87 (72.5%), respectively (OR:
0.562; 95% CI: 0.309, 1.008; P = 0.0532).
Themedian percentage decrease in the rate of all
types of seizure (excluding status epilepticus) dur-
ing the 12-week fixed-schedule titration period
(‘patients with seizure data’ population) was
33.4% for the b.i.d. and 23.8% for the t.i.d. groups
(P = 0.9634 for Van Elteren’s test).
The proportion of responders was similar for
b.i.d. and t.i.d. groups in both the fixed-schedule
titration and continuation phases (Fig. 2).
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Figure 1 Study dosing schedule.
Table 1 Frequently occurring (5% incidence) treat-Safety
A comparable number of patients reported at least
one AE during the fixed schedule titration period in
each group (102 b.i.d., 94 t.i.d.). The corresponding
numbers in the continuation phase for b.i.d. and
t.i.d. groups were 31 and 36, respectively. The
occurrence of AEs during the titration (Table 1)
and continuation periods (not shown) was mostly
balanced between the treatment groups and mostFigure 2 Percentage of responders in all seizure types in
the ITT population during the final 4 weeks of the fixed
titration period and during the last 8 weeks of the flexible
continuation phase.AEs were related to the central nervous system
(CNS). There were nine serious adverse events pos-
sibly or probably related to tiagabine in the b.i.d.
group and two in the t.i.d. group. All except one
occurred during the fixed schedule phase. No clini-
cally significant changes in clinical chemistry, hae-
matology values or vital signs were observed during
the study.ment-emergent adverse events that started in the
fixed-schedule titration period.
Adverse event Patients dosed
with tiagabine
b.i.d. n (%)
Patients dosed
with tiagabine
t.i.d. n (%)
Total patients 123 120
Dizziness 38 (31) 27 (23)
Somnolence 21 (17) 24 (20)
Headache 27 (22) 14 (12)
Tremor 14 (11) 16 (13)
Asthenia 10 (8) 15 (13)
Ataxia 13 (11) 11 (9)
Confusion 10 (8) 10 (8)
Nausea 12 (10) 4 (3)
Pharyngitis 6 (5) 10 (8)
Infection 7 (6) 6 (5)
Depression 8 (7) 2 (2)
Myoclonus 8 (7) 1 (1)
Amblyopia 6 (5) 2 (2)
Amnesia 2 (2) 6 (5)
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Administering tiagabine b.i.d. provides a similar
level of efficacy to t.i.d. dosing, without markedly
affecting the proportion of patients tolerating the
drug during the fixed-schedule titration period. The
proportion of responders in both treatment groups
during the fixed schedule titration and flexible con-
tinuation phases was similar. Our results support
those of a previously published comparison of tia-
gabine regimens.4
There were limited differences between the
treatment regimens in terms of safety findings
and tolerability. Central nervous system related
events such as dizziness and headache were the
most reported symptoms in both dosing groups
and were predominantly of mild intensity. The pre-
sence of a higher number of adverse events during
the fixed-schedule titration period and more fre-
quent severe adverse events with b.i.d. dosing dur-
ing this period suggest that during titration t.i.d. is
better tolerated. However, our results also suggest
that patients with partial seizures who were pre-
viously maintained on a t.i.d. tiagabine dosing sche-
dule may benefit from the use of a more convenient
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